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Abstract. Malaria continues to pose imminent threat to the world population, as the mortality rate 
associated with this disease remains high. Current treatment relies on antimalarial drugs such as 
Artemisinin Combination Therapy (ACT) are still effective throughout the world except in some places, 
where ACT-resistance has been reported, thus necessitating novel approaches to develop new anti-malarial 
therapy. In the light of emerging translational research, several plasmodial targets, mostly proteins or 
enzymes located in the parasite’s unique organelles, have been extensively explored as potential candidates 
for the development of novel antimalarial drugs. By targeting the metabolic pathways in mitochondrion, 
apicoplast or cytoplasm of Plasmodium, the possibility to discover new drugs is tremendous, as they have 
potentials as antimalarial therapeutic targets. This literature review summarizes pertinent information on 
plasmodial targets, especially enzymes involved in specific metabolic pathways, and the strategies used to 
discover new antimalarial drugs. 
 
Keywords: Plasmodium enzymes, metabolic pathways, antimalarial target, drug discovery 
 
 
INTRODUCTION 
 
Despite the reduced numbers of malaria cases in 
the world, the morbidity and mortality rates 
remain disturbing. The World Health 
Organization (WHO) in 2017, reported that 219 
million malaria cases have been registered 
worldwide. From this number, almost 92% of the 
cases occurred in WHO African Region, WHO 
South-East Asia Region (5%) and the Eastern 
Mediterranean (2%) regions (WHO, 2018). 
Malaria is caused by the parasites from genus 
Plasmodium, where infected Anopheles mosquitoes 
play a role as the transmission vector. Human 
infection with Plasmodium is normally associated 
with four species; specifically, Plasmodium 
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falciparum, P. vivax, P. malariae and P. ovale. P. ovale 
that caused malaria in human can be divided into 
two distinct ovale malaria species, which are P. ovale 
curtisi and P. ovale walkeri, after a study conducted 
by researchers from Mahidol University, Bangkok 
and UK Malaria Reference Laboratory, where 
polymorphisms in six loci were observed in 55 
isolates. It was found that two diverse major 
haplotypes of each locus were identified and these 
did not recombine in any of the parasites 
examined (Alemu et al., 2013; Rowe et al., 2006; 
Sutherland et al., 2010) 
The recent distribution of Plasmodium species 
shows that majority of P. falciparum infection 
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occurred in tropical Africa, while P. vivax infection 
happens more in South America, compared to P. 
falciparum. Meanwhile, in South-eastern Asia and 
Western Pacific, both P. falciparum and P. vivax are 
prevalent. Even though P. malariae could arise in 
all malarious areas, the P. malariae prevalence is 
usually low. Meanwhile in tropical Africa, P. ovale 
is prevalent and sometimes P. falciparum and P. 
malariae co-infection is found (Autino et al., 2012). 
However, in the recent years, the fifth human 
malaria parasite, known as P. knowlesi that was 
formerly infecting monkeys has been discovered, 
raising concerns on zoonotic transmission (White, 
2008). P. knowlesi infection occurs only in forested 
area in certain countries in South-East Asia 
(Autino et al., 2012). The zoonotic malaria species 
P. knowlesi has become the main cause of human 
malaria in Malaysian Borneo (Fornace et al., 2016; 
William et al., 2011; Yusof et al., 2016).   
The clinical features shown on malaria 
patients usually appear during parasite’s 
maturation in human blood and the symptoms 
emergence coincides with the release of antigens 
during the host cell rupture (Trampuz et al., 2003). 
According to its severity, malaria is usually 
classified as uncomplicated (or mild) or 
complicated (severe) (Phillips et al., 2017). To 
circumvent severe illness or fatality, an 
appropriate management of malaria is vital. At 
present, malaria treatment according to the 
standard treatment recommended by the WHO, 
is Artemisinin Combination Therapy (ACT) as the 
first line of malaria treatment for countries that 
are prevalent with P. falciparum infection. In areas 
of multidrug resistance (South-East Asia), drugs 
presently used for malaria treatment including 
combination of artemether-lumefantrine or 
artesunate + mefloquine while in Africa 
artemether-lumefantrine, artesunate + 
amodiaquine, or artesunate + sulfadoxine-
pyrimethamine is used. The second line treatment 
could be alternative of ACT, quinine + 
tetracycline or doxycycline or clindamycin. 
Chloroquine is generally used for P. vivax, P.ovale 
and P. malariae. (CDC, 2015; WHO, 2015). 
The reduction of death due malaria nowadays 
is largely contributed by the collective efforts of 
adoption of new-artemisinin-based medicine, 
increased of investments for research and 
development that leads to improvements in 
antimalarial treatments. Jagoe mentioned in the 
Medicine for Malaria Ventures (MMV) that a 
single dose treatment has been introduced in 2018 
for vivax malaria. The current treatment always 
lead to poor compliance because of the treatment 
period; this could replace the current 14 days 
treatment to stop relapse (Jagoe, 2018). The trial 
for the new vivax malaria treatment was 
performed in Brazil, Cambodia, Ethiopia Peru, 
Philippines and Thailand, where they have 
selected 522 malaria patients with confirmed 
infection with P. vivax and normal glucose-6-
phosphate dehydrogenase (G6PD), resulted in 
significantly lower risk of recurrence of P. vivax  as 
compared to placebo in patient with normal 
G6PD activity (Lacerda et al., 2019). 
Many approaches using the latest technology 
has been conducted to develop new drug 
candidates for the treatment of antimalarials, as 
alternative to the currently available treatments. 
Four years ago, a team at MVV lead by Burrows 
and colleagues has established an outline for 
malaria drug design by defining the minimum 
acceptable profile of target candidates and target 
product for developing a novel malaria therapy. 
Target candidate profile (TCP) with their 
mechanism of action has been listed out in their 
review. Each TCP has their own mechanism of 
actions, as for example TCP1 targeted molecules 
that would clear asexual plasmodial blood stages 
in patients, while TCP3 aim the molecule that aids 
in clearing the dormant hypnozoites as prevention 
of relapses due to P. vivax or P. ovale infections.  
Meanwhile, TCP4 and TCP5 have different target 
where TCP4 targeted molecules that can clear the 
liver stage infection. However, TCP5 and TCP6 
action by blocking the transmission, TCP5 
rendering the gametocyte non-functional and 
TCP6 kill the mosquito following a blood meal 
(Burrows et al., 2017). MMV predicted that only 
less than two percent of project for new 
antimalarial will proceed to final stage of clinical 
trial.  
Okombo and Chibale reviewed in 2018 on the 
latest progress of drug candidates as described in 
MMV and the NIH-hosted repository for clinical 
trials. A literature search was performed by 
Okombo and Chibale from articles in the life 
sciences journal archive and PubMED that was 
published in the last five to six years, where it was 
described that the drug candidate for antimalaria 
at present are under various phases of 
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consideration for development. Six drugs were at 
lead optimization stage, five drugs are at 
preclinical stage, three antimalarial drugs 
candidates are already for clinical evaluation and 
additional six drug candidates are in product 
development under patient exploratory stage. 
These current discoveries will require long term 
investments, scientific venture and political 
support to warrant the decrease of disease burden 
globally (Okombo & Chibale, 2018). 
 
1. Antimalarial resistance 
Over the years, the efficacy of most antimalarial 
drugs is declining, which is mainly due to the more 
widespread resistance. This issue is further 
exacerbated by the fact that the compounds 
currently used in malaria treatment share related 
mechanisms of action. This hinders the efforts to 
reduce the morbidity and mortality rates related to 
this disease (Olliaro & Mussano, 2003). Resistance 
of P. falciparum towards antimalarial starting from 
the first report of quinine resistance in 1910, 
followed by chloroquine in 1960 (Blount 1967; da 
Silva & Benchimol, 2014; Tan et al., 2014). An 
analysis of molecular, genetic and biochemical 
approaches to P. falciparum gene resistance 
towards chloroquine has been conducted by Le 
Bras & Durand (2003), which the study aimed to 
elucidate P. falciparum multidrug resistance 1 gene 
(pfmdr1). The authors identified a gene on 
chromosome 5, encoding a P-glycoprotein 
homolog 1 and P. falciparum chloroquine 
resistance transporter (pfcrt) on chromosome 7 as 
the main determinants of chloroquine resistance. 
Their findings have also shown that mutations in 
pfmdr1 and pfcrt genes eventually lead to 
chloroquine resistance. Mutations in these genes 
causes reduction in chloroquine uptake by the 
parasite’s vacuole (Le Bras & Durand, 2003; 
Ibraheem et al., 2014). Chloroquine resistance of 
P. vivax has already grasped a worrying prevalence 
in Indonesia, East Timor and Papua New Guinea. 
Recently, chloroquine resistance of P. vivax 
infections in Guyana, Peru and Brazil has been 
investigated in in vivo studies (Gonçalves et al., 
2014). In the same year, molecular evidence of 
increased resistance to chloroquine and 
sulphadoxine/pyrimethamine has been reported. 
Both in vivo treatment efficacy and molecular 
assays were used to identify the range of P. 
falciparum resistance towards both drugs in two of 
north-east Indian state. The study reported 81.5% 
treatment failure for chloroquine and 13.7% 
treatment failure to sulphadoxine / 
pyrimethamine. Moreover, 99% of the failure had 
mutant pfcrt genotype (76T), while 68% had 
mutant of pfmdr-1 genotyoe (86Y).  The study 
indicates high level of resistance was observed in 
North-east India and it triggered an alarm for 
malaria management in north-east India 
(Mohapatra et al., 2014). Another study conducted 
during 2008−2013 in Kolkata and Purulia, India, 
resulted in a rise of in vitro chloroquine resistance 
to P. falciparum, even after five years following 
chloroquine withdrawal (Das et al., 2017). 
Since chloroquine is no longer used in treating 
P. falciparum infection, a standardized treatment 
using ACT has been employed to replaced 
chloroquine. Presently, ACT is still the most 
effective treatment for malaria since to date, no 
other alternative treatment can match its potency 
(WHO, 2015). However, in an earlier study, 
Rogers et al. (2009) found that artesunate-
mefloquine, a type of ACT antimalarial, has 
started to fail in southern Cambodia (Rogers et al., 
2009). P. falciparum resistance to artemisinin has 
also been identified in the Greater Mekong 
Subregion including Cambodia, Myanmar, Laos, 
Thailand and Vietnam (WHO 2018). The 
mutations in the kelch propeller (K13-propeller) 
domain has been associated with the development 
of artemisinin resistance involving point 
mutations at Y493H, C580Y, M476I, R539T and 
I543T (Ariey et al., 2014; Straimer et al., 2015). The 
development of P. falciparum resistance towards 
artemisinin derivatives is causing limited efficacy 
of the current antimalarial drugs (Ringwald et al., 
2012). An investigation into the efficacy and 
safety of artemisinin-based antimalarials in the 
treatment of uncomplicated malaria for children 
in southern Tanzania indicated that artemether-
lumefantrine (AL) is very efficacious in areas of 
high sulphadoxine–pyrimethamine (SP) resistance 
(Kabanywanyi et al., 2007). More recently, 
Hastings et al. (2014) reported that artemisinin 
component typically shows insignificant 
contribution (<0.0001%) to the therapeutic 
capacity of the most widely used ACTs (Hastings 
& Hodel, 2014). On the other hand, a study to 
determine the efficacy of conventional 
antimalarials against P. knowlesi, the fifth human 
malaria parasite, revealed that it is uniformly 
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highly sensitive to artemisinin, variably and 
moderately sensitive to chloroquine, and less 
sensitive to mefloquine (Fatih et al., 2013). Table 
1 summarized the regions where antimalaria drug 
resistance have been reported with respective 
molecular markers. 
Thus, there is a vital need to identify novel 
targets that can be employed in the improvement 
of the next generation of antimalarial drugs. Since 
antimalarial drugs are a vital component of disease 
control and elimination, potential failure of these 
drugs in the future would hinder the efforts 
dedicated to disease eradication and treatment. 
The aim of this review is to elucidate the 
applicability of enzymes found in Plasmodium spp. 
as possible therapeutic targets in combating 
malaria. In order to achieve this objective, 
pertinent information related to antimalarial 
targets, especially the enzymes involved in specific 
pathways, the mechanism of action of the 
enzymes and inhibitors, as well as the strategies 
used to discover new antimalarial drugs are 
discussed and presented in the following sections.
 
Table 1. Specific regions where antimalaria drug resistance have been reported with their respective 
molecular markers 
Drugs Species Region Molecular marker Reference 
Chloroquine P. falciparum  
Mutation on pfmdr1 
and pfcrt genes 
(Le Bras & Durand, 
2003) 
Chloroquine P. vivax 
Indonesia, East 
Timor, Papua New 
Guinea Guyana, 
Peru and Brazil 
 (Gonçalves et al., 2014) 
Chloroquine 
and 
sulphadoxine 
/pyrimethamine 
P. vivax North-east India 
Mutation on pfmdr1 
and pfcrt genes 
(Mohapatra et al., 2014) 
Chloroquine P. falciparum 
Kolkata and 
Purulia, India 
 (Das et al., 2017) 
Artesunate-
mefloquine 
P. falciparum Southern Cambodia  (Rogers et al., 2009) 
Artemisinin P. falciparum 
Cambodia, 
Myanmar, Laos, 
Thailand and 
Vietnam 
Mutations in the 
kelch propeller 
(K13-propeller) 
(WHO, 2018) 
 
 
Sulphadoxine–
pyrimethamine 
 Tanzania  
(Kabanywanyi et al, 
2007) 
2. Antimalarial target 
Over the years, most of the antimalarial drug 
discovery efforts tend to focus on parasite-
specific processes, such as hemoglobin 
degradation, parasite’s egress from the host cell, 
and host cell invasion by the parasite. As these 
approaches are becoming increasingly ineffective 
in combatting and treating malaria, it is essential 
to conduct further studies aiming to identify new 
targets for the development of antimalarial drugs. 
The findings are expected to facilitate 
construction of new compounds that can interact 
with the target receptor to diminish the malaria 
parasite. Targets such as mitochondrion, 
apicoplast and cytoplasm of Plasmodium have been 
studied extensively in extant studies and their 
potential as drug targets has been elucidated. 
Table 2 summarizes the Plasmodial enzymes in 
metabolic pathways that have been identified as 
drug targets.
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Table 2. Plasmodial enzymes in metabolic pathways as therapeutic targets. 
Metabolic pathway Inhibitor Therapeutic target References 
Iron and heme 
metabolism 
Artemisinin and its 
derivatives 
Pf ring stage activates 
ART 
(Klonis, Creek, & Tilley, 
2013) 
Pyrimidine biosynthesis 
pathway 
Small molecule species 
specific inhibitors of 
Plasmodium falciparum 
DHOD 
Dihydroorotate 
dehydrogenase 
(Patel et al., 2008) 
Triazolopyrimidine-
based 
Dihydroorotate 
dehydrogenase 
(Gujjar et al., 2009) 
Aryl and aralkyl amine-
based triazolopyrimidine 
Dihydroorotate 
dehydrogenase 
(Gujjar et al., 2011) 
SPROUT-designed 
inhibitors (a software 
package for structure-
based drug discovery 
and lead optimization). 
Dihydroorotate 
dehydrogenase 
(Davies et al., 2009) 
Mitochondrial inner 
membrane enzyme 
Tetracyclic 
benzothiazepines 
Cytochrome bc1 (Dong et al., 2011) 
4(1H)-pyridones Cytochrome bc1 (Bueno et al., 2012) 
Mitochondrion 
Heterocyclic 
Quinolones 
NADH: ubiquinone 
oxidoreductase 
(Leung et al., 2012) 
Folate pathway 
Antifolates 
Dihydrofolate reductase 
and dihydropteroate 
synthase 
(Hyde et. al., 2005) 
Sulfur based drugs 
(analogs of 
sulphanilamide) 
Dihydropteroate 
synthase 
(Nzila et. al., 2006) 
Quinazolinones Dihydrofolate reductase (Patel et al., 2017) 
GTP analogue inhibitor 
(8-oxo-GTP) 
GTP cyclohydrolase I 
(Kümpornsin et al., 
2014) 
Glycolytic pathway 
Galloflavin Lactate dehydrogenase (Manerba et al., 2012) 
Itraconazole, 
atorvastatin and 
posaconazole 
Lactate dehydrogenase 
(Penna-Coutinho et al., 
2011) 
Azole-based compound Lactate dehydrogenase (Cameron et al., 2004) 
3-Br-isoxazoline 
Glyceraldehyde-3-
phosphate 
dehydrogenase 
(Bruno et al., 2016) 
Analogues of inorganic 
diphosphate 
T. cruzi hexokinase (Hudock et al., 2005) 
PfHK inhibitors with 
antiparasitic activity 
hexokinase (Davis et al., 2016) 
2.1 The mithochondrian target 
According to Goodman et al., 2017, Plasmodium 
mitochondrion is an effective drug target with 
safe effective drugs for medical use. The 
mitochondrion is an organelle that plays a key role 
in the eukaryotic cell energy production. 
Plasmodium mitochondrion, a single tubular 
organelle structure (6-kb mtDNA) is highly 
fragmented rRNA gen and only encodes three 
genes for proteins (Das et al., 1997; Hikosaka et al., 
2011).  Plasmodium and the host’s mitochondrial 
are different in terms of molecular and their 
function. Plasmodial mitochondrial is essential in 
the parasite’s life cycle (Lunev et al., 2016), where 
mitochondrion dysfunctional can cause cell death. 
An overview of studies examining mitochondria 
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of Plasmodium as a drug target conducted by 
Hikosaka et al. (2015) indicated that the enzymes 
of mitochondrial tricarboxylic acid (TCA) cycle 
and mitochondrial electron transport chain 
(mtETC) are attractive drug targets. TCA cycle, 
also known as Krebs cycle, is one of the important 
stages in aerobic respiration.  It is well-established 
that the substrate for TCA cycle is acetyl-CoA 
from pyruvate oxidation or fatty acid/protein 
degradation. Lunev et al. (2016) also has discussed 
in detail regarding the potential pathways of the 
mitochondrial and carbon metabolisms, such as 
pyrimidine biosynthesis, aspartate metabolism 
and mitochondrial tricarboxylic acid (TCA) cycle 
as drug targets in P. falciparum (Lunev et al., 2016). 
Although P. falciparum possesses all enzymes of 
the TCA cycle, it has been suggested that at least 
the asexual stages do not require TCA cycle for 
energy generation (van Dooren, Stimmler and 
McFadden 2006) and rely on glycolysis and 
fermentation for energy (Vander Jagt et al., 1990). 
Moreover,  Hikosaka et al. (2015) cautioned that 
drug targeting TCA cycle and mtRTC was a 
difficult approach, as it required rigorous 
biochemical analysis due to the complexity 
associated with obtaining intact and pure 
mitochondria from the parasites. Furthermore, 
studies mentioned that during erythrocytic cycle 
of plasmodium, oxidative phosphorylation is not 
crucial for the Plasmodium as the parasites depend 
mainly on glycolysis for the source of energy to 
survive during the blood stage (Ke et al., 2015; 
MacRae et al., 2015; Bryant et al., 1964; Roth et al., 
1988). Thus, Lunev et al., (2016). generally 
believed that the role of mitochondria in the 
parasite during blood stage is mainly for the 
maintenance of inner mitochondrial potential 
Hence, designing antimalarial drugs by targeting 
the mitochondrion, specifically by failing the inner 
mitochondrial potential and inhibit Plasmodium 
growth is still relevant, as it may potentially deliver 
new drugs for malaria treatment.   
Nevertheless, mitochondrial electron 
transport remains as target for the existing and 
new antimalarials. An analysis has suggested that 
a mixture of chloroquine or its analogue, together 
with another drug, inhibits carbon fixation and/or 
increases oxidative stress, where this should 
increase the clearance of P. falciparum from the 
host system (Tewari et al., 2017). Compounds 
such as atovaquone are known to target the 
mitochondrial electron transport chain, since it 
blocks the flux of metabolites through the TCA 
cycle (Ke et al., 2015).The details of the studies of 
enzymes in these pathways are tabulated in Table 
2. 
Even though malaria parasite’s mitochondria 
metabolic processes are limited, and less pathways 
appear during the intraerythrocytic cycle for the 
parasite survival, it is encouraging that various 
number of compounds selectively aiming 
Plasmodium mitochondrion. Inhibition of 
mitochondria resulting in accumulation of free 
fatty acid and triglycerides in the cytoplasm and 
their derivatives, which have toxic effects 
potential on mitochondrial respiration, ketone 
body production , gluconeogenesis and ATP 
synthesis (Olszewska & Szewczyk, 2013). 
 
2.2 Apicoplast target 
Apicoplast (vestigial plastid) is a chloroplast-like 
organelle characterized by a unique non-
photosynthetic plastid. Apicoplast can be found 
in most parasites of Phylum Apicomplexa, a name 
derived from apical complex, except in 
Cryptosporidium spp. (Köhler et al., 1997; McFadden 
et al., 1996). Apical complex is an anterior 
structure that allows the parasite to invade the 
host cells and establish themselves in the host. 
Apicoplast is a specialized organ located below 
apical complex that performs multiple functions 
but its capacity to photosynthesize is limited. In 
addition, it holds a wide range of metabolic 
pathways that can be used by the parasite. Some 
of the product components are critical for the 
host cell invasion (Ralph et al., 2001; Mukherjee & 
Sadhukhan, 2016). However, apicoplast retains 
the typical plastid functions, such as isoprenoid, 
fatty acid, and haem syntheses (Table 1), while 
also carrying cellular processes, such as 
deoxyribonucleic acid (DNA) replication, 
transcription, translation, and post-translational 
modification (Mukherjee & Sadhukhan, 2016). 
Nonetheless, the reason why apicoplast is 
essential to the parasite’s survival is still unknown 
(Lim & McFadden, 2010). 
Apicoplast as an antimalarial drug target has 
been examined by several researchers (Botté et al., 
2012; Mukherjee and Sadhukhan 2016; Ralph, 
D’Ombrain, & McFadden, 2001). According to 
their findings, the apicoplast target for 
antimalarial is based on the metabolic activity in 
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the Plasmodium itself. As reviewed by Mukherjee & 
Sadhukhan (2016), in apicoplast DNA replication, 
gyrase A (GyrA) and gyrase B (GyrB) play an 
important role in Plasmodium, where DNA 
cleavage and wrapping domains were located in 
GyrA subunit, whereas  adenosine triphosphase 
(ATPase) and DNA binding/GyrA interaction 
domains are present in the GyrB subunit, where 
this structure exhibit strong homology to 
Escherichia coli. In E. coli, aminocoumarin drug 
novobiocin inhibits the ATPase activity of GyrB, 
while in P. falciparum the drug was shown to 
competitively inhibit the apicoplast’s ATPase 
activity and DNA replication, which causing a lag 
in conversion of the parasite’s stages from 
trophozoite to schizont stage. Novobiocin also 
disrupt the activity of P. falciparum GyrB ATPase 
that causes the parasite’s death in cultures. On the 
other hand, the review also mentioned 
ciprofloxacin, which shown to inhibit apicoplast 
DNA replication in P. falciparum (Mukherjee & 
Sadhukhan, 2016).  
In a more recent study, Rai et al. (2017) noted 
that understanding of the function of apicoplasts 
will benefit in designing better therapeutics 
through calcium signaling because it plays a vital 
role in the development and growth of 
Plasmodium, specifically in apicoplast 
transcriptional regulation (Cheemadan et al., 2014; 
M. Rai et al., 2017).  Cheemadan et al. (2014) 
studied the role of calcium signaling in the 
transcriptional regulation of the apicoplast 
genome of P. falciparum. In order to assess the 
effect of changing calcium distribution within the 
cell, the transcriptional responses of P. falciparum 
to two calcium ionophores was analysed.  It was 
found that both inhibitors induced overlapping 
but not identical changes of the P. falciparum 
transcriptome. However, both inhibitors caused 
strong inhibition of transcriptional activity of all 
the important genes in the apicoplast genome. 
Due to this situation, the authors identified 
MAL13P1.156, which is a nuclear encoded 
apicoplast targeted protein that transports a 
calcium binding domain. Overexpression of the 
protein causing resistance of P. falciparum towards 
ionomycin and it was proposed that this protein 
possibly play an important role in calcium 
dependent signaling pathways in apicoplast 
(Cheemadan et al., 2014). 
In addition, apical membrane antigen 1 
(AMA1) is one of the components in the invasion 
machinery of Plasmodium. AMA1 was found to be 
an important candidate for malaria vaccine. A 
review beheld at both structural details and 
functional significance of interactions at the 
hydrophobic cleft of AMA1 have been elucidated 
and it is suggested as an ideal target for the 
development of drugs that can prevent host cell 
invasion by malaria parasites (Macraild et al., 
2011). 
 
2.3 Cytoplasmic target 
An apicomplexan including Plasmodium spp., 
Toxoplasma gondii, and Cryptosporidium parvum, as 
well as opportunistic pathogens of 
immunocompromised individuals Eimeria spp. and 
Theileria spp., share distinct morphological features 
and cytoskeletal organization. Cytoskeletal system 
is multifaceted, comprising of interlinking 
filaments and tubules that spread throughout the 
cytoplasm. In Plasmodium, various metabolic 
pathways can be found in the cytoplasm, such as, 
folate metabolism and glycolysis. These metabolic 
pathways consist of hundreds of enzymes that 
may be potential drug targets (Gardner et al., 
2002). A general overview adapted and modified 
from Gardner et al., 2002 on these pathways is 
shown in Figure 1. 
 
2.4 Enzymes involved in folate pathway 
Empirical evidence also indicates that folate 
pathway is vital for synthesizing amino acids, as it 
is important for building of proteins for the 
malaria parasites survival. By referring to previous 
literatures regarding folate pathway, several drugs 
were developed to disrupt folate pathway with the 
aim of developing new treatment and prophylaxis 
for malaria. Folate pathway is also critical in 
providing cofactors for the metabolic events. The 
enzymes in this pathway serve as molecular 
targets, including dihydrofolate reductase 
(DHFR) and dihydropteroate synthase (DHPS). 
DHFR aids in the oxidation of tetrahydrofolate 
(THF) molecule to DHF and its reconversion to 
the THF form (Hyde, 2005). DHPS is an enzyme 
with two binding pockets, one of which binds to 
dihydropterin pyrophosphate (DHPP), while the 
other binds with p-amino benzoic acid (pABA). 
DHPS catalyzes the reaction that produces 7,8-
dihydropteroate from these two substrates. 
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Figure 1. General overview of metabolism pathways and potential target for novel inhibitor in Plasmodium 
spp. Figures adapted and modified from Gardner et al., (2002). 
 
 
Among the antimalarial drugs presently in use, the 
antifolates have emerged as the most promising 
owing to their well-defined molecular targets—
dihydrofolate reductase (DHFR) and 
dihydropteroate synthase (DHPS)—that are also 
involved in the folate metabolic pathway. 
Antifolates are inhibitors of folate synthesis or 
folate conversions and are currently used for 
malaria treatment. These are first-line drugs in 
some of the African countries, as they are a cost-
effective choice for fighting chloroquine-resistant 
malaria (Hyde, 2005). The antifolates have also 
been developed as synergistic combinations of 
DHFR and DHPS inhibitors. Antifolates, such as 
sulfur-based drugs, which are analogs of 
sulfanilamide, can inhibit DHPS. These 
compounds compete with para-aminobenzoic 
acid in the DHPS active site. However, due to 
their inherent toxicity, there is paucity of studies 
on the sulfur-based drugs, which limits their use 
in antimalarial treatment (Nzila, 2006). Another 
evaluation of antimalarial screening of 
quinazolinones was carried out by Patel et al., 
(2017) both computationally as well as in vitro and 
its findings revealed their DHFR inhibitory 
potency. The main contribution of this study 
stems from identifying five out of nineteen potent 
antimalarial molecules (Patel et al., 2017).  
Other enzymes in folate pathways were 
defined in an earlier work by Lee et al. (2001), 
which described the gene that encodes GTP 
cyclohydrolase I (gtp-ch), catalyzing the conversion 
of GTP to dihydroneopterin via triphosphate. 
Polymerase chain reactions and DNA sequencing 
were performed to isolate the gtp-ch gene of P. 
falciparum. The gene was identified by using six 
primers and direct sequencing of this fragment 
discovered an open reading frame that are 
comparable with the predicted protein sequence 
and those of known gtp-ch molecules.  This gene is 
attractive for novel antimalarial therapeutic target 
because it is expressed in blood-stage parasites 
and gtp-ch provides the rate-limiting steps in folate 
pathway, as shown in another microorganism 
(Lee et al., 2001). Years later, Kümpornsin et al. 
(2014) studied the enzymatic activity and genetic 
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complementation for P. falciparum GTP 
cyclohydrolase I (PfGCH1). Its findings indicated 
that this could be a new approach to antimalarial 
drug development, since the assay of this enzyme 
showed an inhibitory effect by 8-oxo-GTP, a 
known GTP analogue inhibitor (Kümpornsin et 
al., 2014). 
 
2.5 Enzymes involved in glycotic pathway 
Finding the alternative molecular targets for 
antimalarial drug design, specifically on the 
energy-generating pathway of carbohydrate 
metabolism is deemed essential in most drug 
design studies. Glycolysis, the metabolic pathway 
for carbohydrate metabolism, is an ancient, 
conserved metabolic energy-producing machinery 
that converts glucose to pyruvate and lactate 
under aerobic and anaerobic conditions, 
respectively. The enzymes in this pathway are 
crucial for parasite survival and growth. It is well-
established that P. falciparum solely depends on 
glycolysis for energy generation and meets its 
energy needs by anaerobic metabolism of glucose 
to lactate (Sabbatani, Fiorino, & Manfredi, 2010). 
Glycolysis occurs in two distinct phases—the 
preparatory and the payoff phase. The 
preparatory phase is the glucose activation phase, 
where phosphorylation of glucose and its 
conversion to glyceraldehyde-3-phosphate takes 
place, while the payoff phase is the extraction 
stage, during which conversion of glyceraldehyde-
3-phosphate to pyruvate, as well as the coupled 
formation of ATP, occurs (Giri, 2016). Ten 
enzymes are involved in glycolysis, namely 
hexokinase, phosphohexose isomerase, 
phosphofructokinase-1, aldolase, triose-
phosphate isomerase, glyceraldehyde 3-phosphate 
dehydrogenase, phosphoglycerate kinase, 
phosphoglycerate mutase, enolase, and pyruvate 
kinase. During anaerobic condition, an additional 
enzyme—lactate dehydrogenase—is required. 
Genome sequence analysis by Gardner et al. 
(2002) has provided a comprehensive 
understanding of the metabolic potential of P. 
falciparum. 
Glycolysis is the key metabolic pathway for 
ATP production in malaria parasite and is pivotal 
for its survival during the Plasmodium intra-
erythrocytic cycle. The glycolysis rate in P. 
falciparum-infected erythrocytes is 20–100 times 
higher than in uninfected erythrocytes, which 
renders them valuable indicators of current 
infections (Iqbal et al., 2004; Singh & Daneshvar, 
2013). In a much earlier study, Roth Jr. et al. (1988) 
demonstrated that nearly all glycolytic enzymes 
were upregulated in P. falciparum-infected red 
blood cells (RBC), which was proportional to the 
parasitemia level. More recently, Kantele & 
Jokiranta (2011) revealed that hexokinase, 
aldolase, enolase, pyruvate kinase, and adenosine 
deaminase were the most markedly upregulated 
enzymes. The functions of each enzyme in the 
glycolytic pathway of malaria parasites have been 
reviewed extensively by Alam et al. (2014). The 
authors also investigated the functions of P. 
falciparum glycolytic enzymes as a part of their 
review. They noted its exceptional structural 
differences and functional features, suggesting 
that these could be exploited as therapeutic 
targets.  
Research on Plasmodium lactate dehydrogenase 
has revealed that pLDH could be a diagnostic 
biomarker, as well as antimalarial inhibitory target 
(Jain et al., 2014; van Niekerk et al., 2016). Manerba 
et al. (2012) conducted their study aiming to verify 
galloflavin (CAS 568-80-9) as a novel inhibitor of 
lactate dehydrogenase. The authors reported that, 
in cultured tumor cells, galloflavin blocked the 
aerobic glycolysis at micromolar concentrations, 
but did not affect the cell respiration or induced 
cell death by triggering apoptosis. Additionally, 50 
commercially-available compounds that have 
been selected through molecular docking 
approach were tested by Penna-Coutinho et al. 
(2011) against P. falciparum lactate dehydrogenase 
(Pf-LDH) and three compounds (itraconazole, 
atorvastatin and posaconazole) have been 
identified with the closest binding energy values 
to NADH. These were subsequently proven 
active in immunoenzymatic assays. The study 
findings further demonstrated that molecular 
docking research can be a reliable approach for 
discovering new antimalarial drugs (Penna-
Coutinho et al., 2011). Following an earlier study 
on azole-based compound, which is also an 
inhibitor of Pf-LDH, Cameron et al. (2004) 
suggested that these compounds have limited 
chances for additional derivatization due to the 
close contacts made within the active site of the 
enzyme. As the authors also noted that they 
appeared to have limited cellular uptake in the 
current form, they called for further development 
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of extended azole-like compounds, which may 
result a beneficial route for the improvement of 
novel antimalarials (Cameron et al., 2004). 
Other enzymes in the glycolytic pathway of 
Plasmodium were also widely studied, the 
glyceraldehyde-3-phosphate dehydrogenase 
(GAPDH) in particular. GAPDH is a important 
glycolytic enzyme that catalyzes the oxidation of 
glyceraldehyde-3-phosphate (G3P) to 1,3-
biphosphoglycerate (1,3-BPG), coupled to the 
reduction of nicotinamide adenine dinucleotide 
(NAD+) to NADH (Bruno et al., 2016). Recent 
investigations have revealed that this enzyme is 
promising as a new malaria diagnostic biomarker 
because native PfGAPDH protein levels were 4–
6 times higher than the current target PfLDH 
(Krause et al., 2017). However, GAPDH has also 
been explored as potential antimalarial drug 
target. Compounds based on the 3-Br-isoxazoline 
scaffold completely inhibit GAPDH from P. 
falciparum by selectively alkylating all four catalytic 
cysteines of the tetramer, but only inhibit 25% of 
human orthologue (hGAPDH) (Bruno et al., 
2016).  
Hexokinase has also been the subject of 
extensive research, as it is the first enzyme in the 
glycolytic pathway. An inhibition study on 
hexokinase of Trypanosoma cruzi, another species 
of blood protozoa, by bisphosphonates, showed 
that these non-hydrolyzable analogues of 
inorganic diphosphate are potent inhibitors of T. 
cruzi hexokinase (Hudock et al., 2005). More 
recently, Davis et al. (2016) attempted to identify 
the inhibitor for P. falciparum hexokinase, where 
57,654 molecules were screened from multiple 
small-molecule collections. Their findings 
revealed that the most potent inhibitors (GSK-
650394) have 50% inhibitory concentrations as 
low as ~1 µM, and some were found to have low-
micromolar concentrations (NCGC 00099116 
and NCGC00099209) that were 50% effective 
against asexual blood stage of P. falciparum 
parasites. 
 
3. Approaches employed in the discovery of 
new antimalarial drugs 
3.1 Computational approach 
Drug design and discovery pipeline comprises all 
the drug development stages, from identifying a 
target to clinical trials for testing the drug on 
human subjects. Hence, drug discovery is typically 
considered a time-consuming and costly process. 
However, computer aided drug design (CADD), 
a computational technology aimed at assisting the 
antimalarial drug discovery process, has become 
indispensable in recent years. It makes use of the 
structural knowledge of either the target 
(structure-based) or known ligands with 
bioactivity (ligand-based) to facilitate the 
identification of likely candidate drugs (Macalino 
et al., 2015).  
A study benefiting from this approach was 
performed by Granchi et al. (2015) with the aim of 
finding new human lactate dehydrogenase 5 
(LDH5) inhibitors. As a part of this investigation, 
an automated docking-based virtual screening 
platform was developed by considering different 
protein conformations and the consensus docking 
strategy. The authors discovered that two of the 
ten of the selected compounds efficiently inhibit 
the enzyme activity via enzymatic assays (Granchi 
et al., 2015). Given that it avoids carrying out 
enzymatic assays of thousands of compounds, 
CADD is highly cost- and time-efficient, as it 
helps optimizing the work in the laboratory. 
Several studies have been performed using both 
structure-based drug design (SBDD) and ligand-
based drug design (LBDD) approaches in finding 
new inhibitors for the enzymes in Plasmodium spp. 
as the target, as summarized in Table 3. 
Huthmacher et al. (2010) conducted their 
study with the goal of elucidating the capability of 
computational methods to foresee the metabolic 
activities during different stages of P. falciparum life 
cycle, which later led to the identification of new 
drug targets. Their findings suggested that the set 
of significant enzymes projected by flux balance 
approach signifies a reliable beginning for further 
drug development (Huthmacher et al., 2010). 
 
3.2 Natural products 
It well-elucidated that countless compounds for 
drug discovery can be found in natural products. 
In the past two decades, their use has declined due 
to the technical difficulties associated with 
screening natural products in high-throughput 
assays compared to molecular targets (Harvey et 
al., 2015). Azas et al., (2002) evaluated potent in 
vitro synergistic antimalarial interactions between 
the extracts of Mitragyna enermis (Willd) O. Kuntze, 
Rubiaceae, Nauclea latifolia (Sm.) Guera senegalensis 
(GMel), Combretaceae and Feretia apodhantera 
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(Del) by conducting isobologram analysis. The 
findings yielded revealed that tetrahydroharman 
isolated from G. senegalensis exhibits antimalarial 
activity with neither cytotoxicity nor genotoxicity 
found in Salmonella Ames test, with and without 
metabolic activation (Azas et al., 2002).  
 
Table 3. Implementation of SBDD and LBDD approaches to find new inhibitors in malaria drug 
discovery 
Methods Species Enzyme target Inhibitor References 
Molecular 
modeling 
Plasmodium 
falciparum 
 
Enoyl reductase 
VRC-007 and VRC-009 
(analogues of N-
benzylidene-4-phenyl-1,3-
thiazol2-amine) 
(Morde et al., 
2009) 
Molecular 
modeling 
Plasmodium 
falciparum 
Dihydroorotate 
dehydrogenase 
KMC-3 and KMC-15 
(derivatives of N-
phenylbenzamide) 
(Desai, Shaikh, & 
Coutinho, 2011) 
Molecular docking 
and 3D-QSAR 
Plasmodium 
falciparum 
Cysteine 
proteases 
Derivatives of peptidyl vinyl 
sulfone 
(Teixeira et al., 
2011) 
3D-QSAR, 
molecular 
dynamics, 
docking, and 
genetic algorithm-
based methods 
Plasmodium 
falciparum 
Dihydroorotate 
dehydrogenase 
Derivatives of 
triazolopyrimidine 
(Shah et al., 2012) 
Modelling the 
evolution of drug 
resistance in 
malaria. 
Plasmodium 
Dihydrofolate 
reductase 
- 
(Hecht & Fogel, 
2012) 
Docking and in 
silico ADMET 
Plasmodium 
falciparum 
S-adenosyl-L-
homocysteine 
hydrolase 
Noraristeromycin, curcumin 
and its derivatives 
(Singh et al., 2013) 
Ligand-based 3D-
QSAR analysis 
and virtual 
screening 
Plasmodium 
falciparum 
Glutathione 
reductase 
N-(2,3-dihydrobenzo[b] 
[1,4]dioxin-6-yl)-2-(5-
isopropyl4-(2-
methoxyethyl)-4H-1,2,4-
triazol-3-ylthio)acetamide 
(Kamaria & 
Kawathekar, 
2014) 
Molecular docking 
Plasmodium 
falciparum 
 
Spermidine 
synthase 
(1R,4R)-(N1-(3-
aminopropyl) -trans-
cyclohexane-1,4-diamine 
and analogue N-(3-
aminopropyl)-
cyclohexylamine 
(Burger et al., 
2015) 
Molecular docking 
Plasmodium 
falciparum 
Transketolase 
6′-Methyl-Thiamin 
Diphosphate 
(Hasan et al., 
2015) 
In silico screening 
Plasmodium 
falciparum 
Enoyl-ACP 
reductase 
Pyrimidine diones 
(Lindert et al., 
2015) 
3D QSAR, 
pharmacophore 
and molecular 
docking 
Plasmodium 
falciparum 
M18 aspartyl 
aminopeptidase 
Derivative of quinine, 
chloroquine, 8-
aminoquinoline and known 
antimalarial M18AAP 
inhibitors (AID743024) 
(Kumari et al., 
2016) 
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More recently, Upadhyay et al. (2014) reported 
antimalarial potential of extracts and compounds 
from the chloroform and n-butanol fractions of 
Ammannia baccifera roots and methanol extract of 
Ammannia coccinea (AC). These extracts are 
commonly used in Chinese and Indian medicine 
as a therapy for diseases. The compounds were 
isolated from the extracted and fractionated dried 
and powdered samples, followed by repeated 
chromatographic separations of the fractions. The 
compounds effectiveness was demonstrated in 
vitro through antiplasmodial activity against P. 
falciparum NF-5. Extracts from AC showed 
potency in antiplasmodial activity and nontoxic to 
Vero cells. The authors thus concluded that the 
selective antiplasmodial activity from these plants 
will be advantageous in antimalarial drug 
development and discovery of safer therapeutics 
(Upadhyay et al., 2014). 
Thiengsusuk & Chaijaroenkul (2013) 
performed an evaluation of antimalarial activities 
of Thai traditional medicine which consist of 27 
medicinal plants and 5 herbal formulations used 
against chloroquine-resistant (K1) and 
chloroquine-sensitive (3D7) P. falciparum clones. 
Their results indicate that that ethanolic extracts 
from 19 investigated plants/herbal formulations 
exhibited promising activity against both K1 and 
3D7 clones of P. falciparum, with < 50% survival 
at the concentration of 50 μg/ml. In addition, 
eight medicinal plants and two herbal 
formulations that were included in this 
investigation showed potent antimalarial activity 
with median range IC50 values < 10 μg/ml 
against K1 or 3D7 P. falciparum clone or both 
(Thiengsusuk & Chaijaroenkul 2013).  
Sethiya et al. (2014) screened methanol extract 
of Evolvulus alsinoides for P. falciparum lactate 
dehydrogenase enzyme inhibitory activity, 
reporting that E. alsinoides possesses a compound 
known as scopoletin that potentially inhibits the 
PfLDH. E. alsinoides is generally recognized as 
Shankhpushpi and is used in traditional remedy for 
malarial treatment by some ethnic populations of 
India (Sethiya et al., 2014). 
 
 
3.3 High throughput screening 
High Throughput Screening (HTS) is a drug-
discovery method that is widely used in the 
pharmaceutical industry. It is an automated 
process that rapidly assays the biological or 
biochemical activity of many drug-like 
compounds. During a typical HTS assay, a 
collection of chemical composites is carefully 
chosen and tested against a biological target to 
evaluate the strength of the related inhibition or 
activation signal (Malo et al., 2006).  In order to 
successfully identify LDH inhibitors from library 
of a small molecule compound, two label-free 
high-throughput assays were planned using a 
kinetic high-throughput screen (VanderPorten et 
al., 2013). In addition, examination on antimalarial 
elements from Berberis thunbergii and Eugenia rigida 
by automated HTS, using UPLC-MS-ELSD-PDA 
yielded two triterpenoids, namely α-betulinic acid 
and β-betulinic acid, that were acknowledged as 
antimalarial active elements from HTS hits of E. 
rigida (Zhang et al., 2014) 
High throughput screening is not only 
beneficial in the search for antimalarial drugs but 
is also indispensable in the discovery of small 
molecules that can interfere malaria transmission. 
Plouffe et al. (2016) developed a serum-free one-
step assay for malaria transmission-blocking 
activity, which allowed them to analyze 13,983 
known and new compounds. The authors noted 
that more than 90% recognized antimalarial drugs 
do not show activity to the late-stage gametocytes. 
Another high-throughput matrix screening 
approach was tested by Mott et al. (2015) on 
13,910 approved and investigational drugs, 
allowing the researchers to identify several 
synergistic and antagonistic antimalarial drug 
combinations. 
 
 
CONCLUSION 
 
 
Malaria is a global issue, with the ongoing malaria 
transmission, there is a possibility for drug 
resistance to occur through increasing 
introduction of parasites to suboptimal drug 
levels. The growing resistance of P. falciparum to 
the established antimalarial drugs highlights the 
need for developing alternative drug regimens. 
Thus, identifying compounds that may disrupt the 
enzymes activities that have high control over the 
pathway’s flux may lead to the discovery of novel 
and effective antimalarial drugs. 
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